검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-IL12/23 or anti-IL23 - Risankizumab (Anti-IL12/23 or anti-IL23 - Risankizumab) University of Calgary·Crohn Disease 3 trials |
|---|---|
Overview Program | Anti-IL12/23 or anti-IL23 - Risankizumab |
Overview Company | University of Calgary |
Overview Modality | ANTIBODY |
Overview Target | Crohn Disease |
Overview Indication | Crohn Disease |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate response to anti-TNF-α or anti-IL12/2 |
MoA Biomarker | biomarkers independently predicted survival |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.. Psoriasis is an immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Despite multiple available treatmen… |
Clinical Data Tier / Score | A · 23 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Anti-IL12/23 or anti-IL23 - Risankizumab (Anti-IL12/23 or anti-IL23 - Risankizumab) University of Calgary·Crohn Disease 3 trials |
|---|---|
Overview Program | Anti-IL12/23 or anti-IL23 - Risankizumab |
Overview Company | University of Calgary |
Overview Modality | ANTIBODY |
Overview Target | Crohn Disease |
Overview Indication | Crohn Disease |
Overview Phase | APPROVED |
Overview Status | RECRUITING |
MoA Mechanism | with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate response to anti-TNF-α or anti-IL12/2 |
MoA Biomarker | biomarkers independently predicted survival |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.. Psoriasis is an immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life. Although there is currently no cure for psoriasis, various treatment strategies allow sustained control of disease signs and symptoms. Despite multiple available treatmen… |
Clinical Data Tier / Score | A · 23 |
Clinical Program phase | APPROVED |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교